Latest news and press releases about Abeona Therapeutics Inc. (ABEO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Price
| Price | $5.37 |
| Market Cap | $306M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -3.81 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.69% |
| Return on Invested Capital | -39.66% |
| Return on Assets | -35.03% |
| Gross Margin | 56.63% |
| Operating Margin | -327.64% |
| Net Margin | -246.42% |
Related companies: ARCT · ASMB · ELDN · FHTX · HUMA · PBYI · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ABEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks